With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. The company is developing novel miotic formulations for a once-daily eye drop to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma and age-related macular degeneration. Additionally, Visus Therapeutics has entered into a worldwide exclusive licensing agreement with DelSiTech Ltd, a leader in advanced, biodegradable, silica-based, controlled-release materials, to develop novel drug delivery technology that can help optimize the clinical benefit of ophthalmic therapies.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $20M
Founded date: 2019
Investors 1
| Date | Name | Website |
| 18.04.2022 | Life Scien... | lspvc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.08.2021 | - | $20M | Life Scien... |
Mentions in press and media 5
| Date | Title | Description |
| 12.08.2021 | Visus Therapeutics lands $20M to develop eye drop that corrects vision loss | Visus Therapeutics, a Seattle-based startup developing a presbyopia-correcting eye drop, raised $20 million. The fresh cash comes just six months after the company raised $36 million. Backers in this round include LSP, Sage Partners, Johnso... |
| 11.08.2021 | Visus Therapeutics Raises $20M in Funding | Visus Therapeutics, Inc., a Seattle, WA- and and Orange County, Calif.,-based based clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, raised $20m in fu... |
| 10.08.2021 | Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners | Proceeds will support clinical and commercial efforts for lead asset BRIMOCHOL™ under investigation for presbyopia as well as new research and development activities in the Company’s drug development pipeline Strengthens its Board of Direct... |
| 10.03.2021 | Visus Therapeutics raises $36M from J&J’s VC arm, others to develop eye drop that treats presbyopia | Visus Therapeutics, a Seattle-based startup developing a presbyopia-correcting eye drop, raised $36 million. Johnson & Johnson Innovation, the venture capital arm of J&J, invested in the Series A round, in addition to RTW Investment... |
| 09.03.2021 | Visus Therapeutics Raises $36M in Series A Financing | Visus Therapeutics Inc., a Seattle, WA- Orange County, Calif.-based based clinical-stage pharmaceutical company developing a presbyopia-correcting eye drop, closed a $36m Series A financing. Backers included Johnson & Johnson Innovation... |